My Account Log in

2 options

Effective drug regulation : a multicountry study / by Sauwakon Ratanawijitrasin, Eshetu Wondemagegnehu.

Ebook Central Academic Complete Available online

View online

Ebook Central College Complete Available online

View online
Format:
Book
Government document
Author/Creator:
Ratanawijitrasin, Sauwakon.
Contributor:
Wondemagegnehu, Eshetu.
Language:
English
Subjects (All):
Drugs--Law and legislation.
Drugs.
Pharmaceutical policy.
Physical Description:
x, 149 p. : ill.
Edition:
1st ed.
Place of Publication:
[Geneva] : World Health Organization, 2002.
Language Note:
English
Summary:
Drugs play a crucial role in saving lives, restoring health, and preventing diseases and epidemics. But they need to be safe, efficacious, of good quality, and used rationally. This means that their production, import/export, storage, supply and distribution should be subject to government control through prescribed norms and standards and an effective regulatory system. Substandard and counterfeit drugs proliferate primarily in an environment where drug regulation has proved ineffective. This publication presents a synthesis of studies on drug regulation carried out in 10 countries: Australia, Cuba, Cyprus, Estonia, Malaysia, the Netherlands, Tunisia, Uganda, Venezuela, and Zimbabwe in 1998-1999. It gives an overview of the development of drug regulation in these countries as well as the resources available and the strategies applied in drug regulation implementation at the time the studies were conducted. An analysis of the strengths and weaknesses in drug regulation in these countries is also provided.
Contents:
Intro
CONTENTS
1. DRUG REGULATION: OBJECTIVES AND ISSUES
1.1 Drugs as an instrument of public health
1.2 Controlling private behaviour for public purposes
1.3 Objectives and organization of this report
2. MULTICOUNTRY STUDY ON EFFECTIVE DRUG REGULATION
2.1 Project rational and development
2.2 Study objectives
2.3 Method of study
2.4 Drug regulation from a comparative perspective
3. PROFILE OF THE COUNTRIES
3.1 General background
3.2 Political environment
3.3 Pharmaceutical sector environment
4. REGULATORY FRAMEWORK
4.1 Missions and goals of drug regulation
4.2 Domains of control
4.3 Other non-regulatory pharmaceutical functions
4.4 National drug policy
4.5 Historical development of drug regulation
5. REGULATORY CAPACITY
5.1 Legal basis, organizational structure and authority
5.2 Human resources
5.3 Financing drug regulation
5.4 Planning, monitoring and evaluating implementation
5.5 Problems encountered and strengths identified
5.6 Political influence and accountability
6. LICENSING OF MANUFACTURING, DISTRIBUTION AND RETAIL SALE
6.1 Power and process
6.2 Human resources
6.3 Paying for licensing
6.4 Performance
7. INSPECTION AND SURVEILLANCE
7.1 Power and process: comparing structures and processes
7.2 Human resources
7.3 Paying for inspection
7.4 Planning, process and performance
8. PRODUCT ASSESSMENT AND REGISTRATION
8.1 Power and process
8.2 Human resources
8.3 Paying for registration
8.4 Performance
8.5 Adverse drug reaction monitoring
8.6 Clinical trials
9. CONTROL OF DRUG PROMOTION AND ADVERTISING
9.1 Power and process: comparing structures and processes
9.2 Performance
10. DRUG QUALITY CONTROL LABORATORY
10.1 Power and process
10.2 Human resources
10.3 Paying for quality control.
10.4 Performance
11. ASSESSING REGULATORY PERFORMANCE
11.1 Assessing government functions: an essential part of policy-making
11.2 Monitoring and evaluation system
11.3 Monitoring and evaluating the effectiveness of drug regulation
11.4 Monitoring and evaluating the efficiency of drug regulation
11.5 Monitoring and evaluating the accountability and transparency of drug regulation
11.6 Availability of information for assessment
12. CONCLUSIONS AND RECOMMENDATIONS FOR EFFECTIVE DRUG REGULATION
12.1 Conclusions related to regulatory structures
12.2 Conclusions related to regulatory processes
12.3 Recommendations for effective drug regulation.
Notes:
"This report is a synthesis of the results of the multicountry studies carried out by the WHO Essential Drugs and Medicines Policy Unit (EDM)."--P. ix.
Includes bibliographical references.
ISBN:
1-280-06038-7
92-4-068029-2
9786610060382
OCLC:
935263257

The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.

Find

Home Release notes

My Account

Shelf Request an item Bookmarks Fines and fees Settings

Guides

Using the Find catalog Using Articles+ Using your account